Inhibition of human cytochrome P450 1B1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in culture

Journal of Biochemical and Molecular Toxicology

Volumn 21, Issue 3, 2007, Pages 101-109

  Mahadevan, Brinda ^a   Luch, Andreas ^a,b   Atkin, Jennifer ^a   Haynes, Melanie ^a   Nguyen, Tuan ^a   Baird, William M ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Chemical inhibition; Cytochrome P450; Dibenzo a,l pyrene; DNA adducts; Polycyclic aromatic hydrocarbons

Indexed keywords

2,4,3',5' TETRAMETHOXYSTILBENE; CYTOCHROME P450 1B1; CYTOCHROME P450 INHIBITOR; DIBENZO[A,L]PYRENE; EMODIN; EPOXIDE; ETHOXYRESORUFIN DEETHYLASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL LINE; CELL STRAIN MCF 7; CULTURE MEDIUM; DNA ADDUCT; DNA BINDING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE INDUCTION; HUMAN; MICROSOME; PROTEIN FUNCTION;

ARYL HYDROCARBON HYDROXYLASES; BENZOPYRENES; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; ENZYME ACTIVATION; HUMANS; MICROSOMES;

CRICETULUS GRISEUS;

EID: 34447519048     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20168     Document Type: Article

References (39)

1. Luch A, Baird WM. Metabolic activation and detoxification of polycyclic aromatic hydrocarbons. In: Luch A, editor. The carcinogenic effects of polycyclic aromatic hydrocarbons. London: Imperial College Press; 2005. pp 19-96.
2. Luch A. Nature and nurture-lessons from chemical carcinogenesis. Nat Rev Cancer 2005;5:113-125.
3. Ioannides C, Parke DV. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab Rev 1993;25:485-501.
4. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer J Biol Chem 2004;279:23847-23850.
5. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, Nebert DW. Oral exposure to benzo[a]pyrene in the mouse: Detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol 2004;65:1225-1237.
6. Uno S, Dalton TP, Dragin N, Curran CP, Derkenne S, Miller ML, Shertzer HG, Gonzalez FJ, Nebert DW. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune Damage independent of total-body burden and clearance rate. Mol Pharmacol 2006;69:1103-1114.
7. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979-2984.
8. Luch A, Coffing SL, Tang YM, Schneider A, Soballa V, Greim H, Jefcoate CR, Seidel A, Greenlee WF, Baird WM, Doehmer J. Stable expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and metabolically catalyzed DNA adduct formation of dibenzo[a,l]pyrene, Chem Res Toxicol 1998;11:686-695.
9. Shimada T, Oda Y, Gillam EM, Guengerich FP, Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos 2001;29:1176-1182.
10. Luch A, Kishiyama S, Seidel A, Doehmer J, Greim H, Baird WM. The K-region trans-8,9-diol does not significantly contribute as an intermediate in the metabolic activation of dibenzo[a,l]pyrene to DNA-binding metabolites by human cytochrome P450 1A1 or 1B1. Cancer Res 1999;59:4603-4609.
11. Luch A, Schober W, Greim H, Doehmer J, Jacob J, Seidel A, Baird WM. Metabolic activation of dibenzo[a,l]pyrene by cytochrome P450 enzymes to stable DNA adducts occurs exclusively through the formation of the (-)-trans(11R,12R)-diol. Polycycl Aromat Compds 2000;21:87-98.
12. Ralston SL, Lau HHS, Seidel A, Luch A, Platt KL, Baird WM. The potent carcinogen dibenzo[a,l]pyrene is metabolically activated to fjord-region 11,12-diol 13,14-epoxides in human mammary carcinoma MCF-7 cell cultures. Cancer Res 1994;54:887-890.
13. Ralston SL, Seidel A, Luch A, Piatt KL, Baird WM. Stereoselective activation of dibenzo[a,l]pyrene to (-)-anti(11R,12S,13S,14R)- and (+)-syn(HS,12R,13S,14R)-11,12-diol-13,14-epoxides which bind extensively to deoxyadenosine residues of DNA in the human mammary carcinoma cell line MCF-7. Carcinogenesis 1995;16:2899-2907.
14. Cavalieri EL, Rogan EG, Higginbotham S, Cremonesi P, Salmasi S. Tumor-initiating activity in mouse skin and carcinogenicity in rat mammary gland of dibenzo[a]pyrenes: The very potent environmental carcinogen dibenzo[a,l]pyrene. J Cancer Res Clin Oncol 1989;115:67-72.
15. Cavalieri EL, Higginbotham S, RamaKrishna NVS, Devanesan PD, Todorovic R, Rogan EG, Salmasi S. Comparative dose-response tumorigenicity studies of dibenzo[a,l]pyrene versus 7,12-dimethylbenz[a]anthracene, benzo[a]pyrene and two dibenzo[a,l]pyrene dihydrodiols in mouse skin and rat mammary gland. Carcinogenesis 1991;12:1939-1944.
16. Higginbotham S, RamaKrishna NVS, Johansson SL, Rogan EG, Cavalieri EL. Tumor-initiating activity and carcinogenicity of dibenzo[a,l]pyrene versus 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene at low doses in mouse skin, Carcinogenesis 1993;14:875-878.
17. LaVoie EJ, He ZM, Meegalla RL, Weyand EH. Exceptional tumor-initiating activity of 4-fluorobenzo[j]fluoranthene on mouse skin: Comparison with benzo[j] fluoranthene, 10-fluorobenzo[j]fluoranthene, benzo[a] pyrene, dibenzo[a,l]pyrene and 7,12-dimethylbenz[ a] anthracene, Cancer Lett 1993;17:7-14.
18. Arif JM, Smith WA, Gupta RC. Tissue distribution of DNA adducts in rats treated by intramammillary injection with dibenzo[a,l]pyrene, 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene. Mutat Res 1997;378:31-39.
19. Arif JM, Smith WA, Gupta RC. DNA adduct formation and persistence in rat tissues following exposure to the mammary carcinogen dibenzo[a,l]pyrene. Carcinogenesis 1999;20:1147-1150.
20. Mahadevan B, Luch A, Bravo CF, Atkin J, Steppan LB, Pereira C, Kerkvliet NL, Baird WM. Dibenzo[a,l]pyrene induced DNA adduct formation in lung tissue in vivo. Cancer Lett 2005;227:25-32.
21. Heidel SM, MacWilliams PS, Baird WM, Dashwood M, Buters JTM, Gonzalez FJ, Larsen MC, Czuprynski C, Jefcoate CR. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene. Cancer Res 2000;60:3454-3460.
22. Nishimura N, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003;123:369-375.
23. Luch A, Friesel H, Seidel A, Platt KL. Tumor-initiating activity of the (+)-(S, S)- and (-)-(R, R)-enantiomers of trans-11,12- dihydroxy-11,12-dihydrodibenzo[a,l]pyrene in mouse skin. Cancer Lett 1998;136:199-128.
24. Ralston SL, Lau HHS, Seidel A, Luch A, Platt KL, Baird WM. Identification of dibenzo[a,l]pyrene-DNA adducts formed in cells in culture and in mouse skin. Polycycl Aromat Compds 1994;6:199-206.
25. Melendez-Colon VJ, Luch A, Seidel A, Baird WM. Cancer initiation by polycyclic aromatic hydrocarbons results from formation of stable DNA adducts rather than apurinic sites. Carcinogenesis 1999;20:1885-1891.
26. Buters JTM, Mahadevan B, Quintanilla-Martinez L, Gonzalez FJ, Greim H, Baird WM, Luch A. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. Chem Res Toxicol 2002;15:1127-1135.
27. 35S]phosphorothioate labeling and HPLC. Carcinogenesis 1991;12:885-893.
28. Nebert DW, Vesell ES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci 2006;27:580-586.
29. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450-structure, mechanism, and biochemistry. New York: Plenum Press; 1995. pp 473-535.
30. Shimada T. Human cytochrome P450 1B1 and chemical carcinogenesis. Rev Toxicol 2000;3:139-166.
31. Guengerich FP, Chun YJ, Kim D, Gillam EM, Shimada T. Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies. Mutat Res 2003;523-524:173-182.
32. Nebert DW, Roe AL, Dieter MZ, Solis WA, Yang Y, Dalton TP. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control and apoptosis. Biochem Pharmacol 2000;59:65-85.
33. Marston CP, Pereira C, Ferguson J, Fischer K, Hedstrom O, Dashwood WM, Baird WM. Effect of a complex environmental mixture from coal tar containing polycyclic aromatic hydrocarbons (PAH) on the tumor initiation, PAH-DNA binding and metabolic activation of carcinogenic PAH in mouse epidermis. Carcinogenesis 2001;22:1077-1086.
34. Mahadevan B, Marston CP, Dashwood WM, Li Y, Pereira C, Baird WM. Effect of a standardized complex mixture derived from coal tar on the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons in human cells in culture. Chem Res Toxicol 2005;18:224-231.
35. Katz AK, Carrell HL, Glusker JP. Dibenzo[a,l]pyrene (dibenzo[def,p]chrysene): Fjord-region distortions. Carcinogenesis 1998;19:1641-1648.
36. Mahadevan B, Marston CP, Luch A, Dashwood WM, Brooks E, Pereira C, Doehmer J, Baird WM. Competitive inhibition of carcinogen-activating CYP1A1 and CYP1B1 enzymes by a standardized complex mixture of PAH extracted from coal tar. Int J Cancer 2007;120:1161-1168.
37. Wang HW, Chen TL, Yang PC, Ueng TH. Induction of cytochromes P450 1A1 and 1B1 by emodin in human lung adenocarcinoma cell line CL5. Drug Metab Dispos 2001;29:1229-1235.
38. Zhang S, Qin C, Safe SH. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: Effects of structure and cell context. Environ Health Perspect 2003;111:1877-1882.
39. Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 2001;61:8164-8170.